期刊文献+

△Np73基因沉默对结肠癌细胞5-氟尿嘧啶化疗敏感性的影响

Effect of △Np73 silencing on 5-FU chemotherapy sensitivity in colon cancer ceils
原文传递
导出
摘要 目的探讨小干扰RNA(siRNA)调节导致的△Np73抑制对结肠癌细胞SW6205-氟尿嘧啶(5-FU)药物敏感性的影响,为结肠癌治疗提供新途径。方法将△Np73 siRNA转染入SW620结肠癌细胞,观察其对结肠癌细胞△Np73表达的影响。并与5-FU联合使用,四甲基偶氮唑盐比色(MTT)法检测细胞活力,流式细胞技术检测细胞凋亡。分别将转染△Np73 siRNA和阴性对照siRNA的SW620细胞注射裸鼠成瘤,瘤中注射5-FU观察体内肿瘤的生长情况。结果△Np73 siRNA可显著抑制SW620结肠癌细胞△Np73的表达,但本身均不能抑制SW620结肠癌细胞的生长。同时应用△Np73 siRNA和5-FU共同处理的SW620细胞的凋亡率达到42.9%,显著高于单纯5-FU处理组(18.9%)和单纯△Np73处理组(8.8%)。在转染△Np73 siRNA的成瘤小鼠的瘤中注射5-FU,能明显抑制癌细胞体外生长(t=15.32,P〈0.05)。结论△Np73 siRNA可通过抑制△Np73的表达,从而增强对化疗药物的敏感性。 Objective To investigate the effect of small interfering RNA (siRNA) mediated silencing of △Np73 on 5-FU chemotherapy sensitivity in SW620 colon cancer cells and provide new treatment approach for the colon cancer. Methods siRNAs were transfected into SW620 colon cancer ceils. The expression of △Np73 was observed. Cell viability of colon cancer cells were measured by MTr assay and cell apoptosis was assessed with flow cytometry after treatment of control siRNA or △Np73 siRNA or combined with 5-FU, respectively. The tumorigenesis was assessed by injecting △Np73 siRNA or control siRNA transfected SW620 colon cancer cells into nude mice, followed by treatment with 5-FU in the tumors. Results △Np73 siRNA was able to strongly inhibit △Np73 expression, however, it did not inhibit the growth of cells. Combination treatment with △Np73 siRNA and 5-FU produced significant higher apoptotic cell(42. 9% ) as compared with those with 5-FU treatment( 18.9% ) alone or those with △Np73 siRNA(8.8% ) alone. The treatment with 5-FU in the xenografts derived from △Np73 siRNA transfeeted SW620 ceils in nude mice can inhibitor tumor growth significantly ( t = 15.32, P 〈 0. 05 ). Conclusion △Np73siRNAs can specifically repress the expression of △Np73. Thus it sensitizess the cells to 5-FU chemotherapy in colon cancer.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2009年第4期455-458,共4页 Chinese Journal of Laboratory Medicine
关键词 结肠肿瘤 RNA 小分子干扰 氟尿嘧啶 核蛋白质类 肿瘤抑制蛋白质类 Colonic neoplasms RNA, small interfering Fluorouracil Nuclear proteins Tumor suppressor proteins
  • 相关文献

参考文献8

  • 1易晓芳,丰有吉.肿瘤多药耐药机制的研究[J].中国实用妇科与产科杂志,2004,20(3):185-187. 被引量:9
  • 2Labialle S, Gayet L, Marthinet E, et al. Transcriptional regulators of the human multdrug resistance 1 gene. Biochem Pharmacol, 2002,64:943-948.
  • 3Yang A, Kaghad M, Caput D, et al. On the shoulders of giants : p63, p73 and the rise of p53. Trends Genet, 2002,18:90-95.
  • 4Zaika AI, Slade N, Erster SH, et al. DehaNp73, a dominant negative inhibitor of wild type p53 and TAp73, is up regulated in human tumors. J Exp Med, 2002,196:765-780.
  • 5Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res, 2005,11:8372-8383.
  • 6Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73 : a newly identified isoform of human p73. Cancer Res, 2002,62:636-641.
  • 7Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ, 2001,8 : 1213-1223.
  • 8Bergamaschi D, Gasco M, Hiller L, et al. Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 2003,3 : 387-402.

二级参考文献26

  • 1[1]Biedler JL,Riehm H.Cellular resistance to actinomycin D in Chinese hamster cells in vitro:cross-resistance,radioautographic,and cytogenetic studies.Cancer Res,1970,30(4):1174-1184
  • 2[2]Higgins CF.ABC transporters:from microorganisms to man.Ann Rev Cell Biol,1992,8:67-113
  • 3[3]Juliano RL,Ling V.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.Biochem Biophys Acta,1976,455(1:152-162
  • 4[4]Labialle S,Gayet L,Marthinet E,et al.Transcriptional regulators of the human multidrug resistance Ⅰ gene:recent views.Biochem Pharmacol,2002,64(5-6):943-938
  • 5[5]Stein WD.Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.Physiol Rev,1997,77(2:545-590
  • 6[6]Hipfner DR,Deeley RG,Cole SP.Structural,mechanistic,and clinical aspects of MRP1.Biochem Biophys Acta,1999,1461(2:359-376
  • 7[7]Borst P,Evers R,Kool M,et al.A family of drug transporters:the multidrug resistance-associated proteins.J Natl Cancer Inst,2000,92(6):1295-1302
  • 8[8]Scheper RJ,Broxterman HJ,Scheffer GL,et al.Overexpression of a M(r) 110000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.Cancer Res,1993,53(7):1475-1479
  • 9[9]Chen YN,Mickley LA,Schwartz AM,et al.Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.J Biol Chem,1990,265(17):10073-10080
  • 10[10]Lee JS,Scala S,Matsumoto Y,et al.Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.J Cell Biochem,1997,65(4):513-526

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部